Are the Ozempic Clinics Popping Up All Over Houston Actually Legit?
Some are. Some are not. The gap between those two categories is wide enough to land you in the ER.
Are the Ozempic Clinics Popping Up All Over Houston Actually Legit?
Some are. Some are not. The gap between those two categories is wide enough to land you in the ER.
The Scene on Every Corner
Drive the Katy Freeway service road near FM 1463 on a Tuesday afternoon and count the signs: Slim Studio, LeanRx Wellness, Rejuvenate Med Spa — Semaglutide Available. Take Kuykendahl Road through The Woodlands and you’ll find another cluster near the Creekside Park shopping centers, usually tucked between a nail salon and a smoothie bar. Around the Galleria, the branding gets more upscale — concierge lobbies on Post Oak and Westheimer, tasteful sans-serif fonts, hushed waiting rooms. But the core product is often identical: a semaglutide injection, dispensed fast, for a monthly fee.
Harris County has seen a documented explosion of GLP-1 clinics since 2022. No state agency maintains a consolidated count. TDLR doesn’t track facilities by treatment type. Nobody knows exactly how many there are. The growth makes economic sense — the Houston metro’s adult obesity rate hovers between 34 and 36 percent, consistently among the highest of any large American city. The drugs work; the clinical evidence for semaglutide and tirzepatide is strong. And when brand-name Wegovy listed at roughly $1,350 a month before coupons or insurance, compounded semaglutide at $250–$400 from a 503A or 503B pharmacy looked like an obvious workaround. Clinics that could offer it drew lines.
The result is a market that runs from legitimate obesity medicine practices staffed by board-certified physicians down to what are, functionally, subscription services — fill out a web form, receive a vial in the mail, get minimal contact with anyone who went to medical school. That range is genuinely hard to overstate. Here’s how to figure out which kind you’re walking into.
What Texas Law Guarantees You — and Where It Falls Apart
Texas law requires a physician-patient relationship before a prescription drug is dispensed. For GLP-1 medications prescribed via telemedicine, the Texas Medical Board requires a visit that meets clinical standards for evaluation — documented medical history, real assessment, ongoing responsibility for your care. The corporate practice of medicine doctrine prohibits non-physicians from owning a medical practice. A private equity group can’t just hire doctors to prescribe on command.
In practice, almost every clinic operating at scale uses a Management Services Organization structure — an MSO. The MSO, which non-physicians can own, runs the website, billing, scheduling, and marketing. A separately structured medical practice, nominally owned by a physician, handles prescribing. The two entities contract with each other. This is legal.
It is also where accountability goes to die. When the MSO controls hiring, firing, compensation, and patient volume targets, the physician of record often becomes functionally nominal — signing off on protocols they may never personally apply, seeing patients they may never actually see. If something goes wrong, the question of who bears clinical responsibility gets murky fast. The TMB can sanction the physician of record. It has no jurisdiction over the MSO.
TDLR licenses the physical facility. It doesn’t credential clinical staff or review prescribing protocols. The Secretary of State registers the business entities. No single agency sees the complete picture. That’s not an accident of oversight — it’s a gap nobody has closed, and the clinics that operate poorly know it.
The Compounding Pharmacy Problem
From 2022 through early 2025, compounded semaglutide existed in a regulatory gray zone that benefited clinics enormously. The FDA had placed semaglutide on its drug shortage list, which legally permitted 503A and 503B compounding pharmacies to copy the drug. Clinics sourced from those pharmacies and passed the savings to patients.
In early 2025, the FDA declared the shortage resolved. That closed the exemption. 503A pharmacies — traditional patient-specific compounders — generally can’t continue producing compounded semaglutide for general dispensing once the shortage designation ends. 503B outsourcing facilities, which supply larger volumes to clinics, faced a compliance deadline the FDA extended under industry pressure, but the legal direction is clear: this ends.
If a clinic is still offering compounded semaglutide at $299 a month and telling you it’s legally equivalent to Ozempic, ask directly which pharmacy is compounding it. Get the pharmacy’s name. Look it up yourself at the Texas State Board of Pharmacy’s license verification site (pharmacy.texas.gov). If it’s out of state, confirm it holds an active non-resident pharmacy license in Texas. If the clinic can’t tell you where your medication is being compounded, stop there. That’s not a paperwork technicality. That’s a serious problem.
There’s a narrow, defensible use case for continued compounding: patients with documented allergies to inactive ingredients in the brand-name formulations. That’s different from bulk compounded semaglutide dispensed to thousands of weight-loss patients with no individualized clinical justification. Tirzepatide — the active ingredient in Mounjaro and Zepbound — had its own shortage designation following the same trajectory. Same questions apply.
What a Legitimate Intake Should Actually Look Like
Before any clinic writes you a GLP-1 prescription, the minimum defensible intake includes a documented medical history covering prior weight-loss attempts, current medications, family history of thyroid cancer and pancreatitis, and any eating disorder history. A metabolic panel, complete blood count, and HbA1c should be drawn. Thyroid function usually is too.
Houston Methodist’s Bariatric and Metabolic Institute and UTHealth Houston’s Division of Endocrinology, Diabetes and Metabolism both run structured obesity medicine programs where this is routine. Physicians at those institutions will tell you — and have told me — that semaglutide is a serious medication. Nausea and vomiting severe enough to cause dehydration and electrolyte imbalance. Documented pancreatitis cases. A black-box warning on thyroid C-cell tumors. And an emerging body of literature on gastroparesis — delayed gastric emptying that, in a subset of patients, becomes severe and doesn’t resolve when they stop the drug. A practice that isn’t equipped to manage these complications, including escalating to a gastroenterologist or emergency physician, should not be prescribing it. Full stop.
The intake should involve a real physician. Not a questionnaire reviewed asynchronously by someone you’ll never speak to. Not a chatbot intake screen dressed up as a medical visit. A synchronous video call with the prescribing physician or a licensed clinician under direct supervision, in which your specific history is reviewed and your questions get real answers — documented in a medical record you can access.
Ask any clinic you’re considering: What labs do you require before prescribing, and who reviews them? What happens if I develop severe nausea or abdominal pain? Can I reach the prescribing physician directly? How they answer — and how fast and confidently they answer — will tell you most of what you need to know.
Price Comparison for Houston-Area GLP-1 Providers
Here’s what CityDesk Houston found contacting and reviewing published pricing from five categories of local providers. All figures reflect mid-2025 and require direct verification.
Brand-name Wegovy through a traditional pharmacy: List price roughly $1,350/month without insurance. Medicare doesn’t cover it for weight management. This is the FDA-approved product. (Note: Ozempic carries FDA approval for Type 2 diabetes; Wegovy for chronic weight management. Clinics prescribing Ozempic off-label for weight loss are doing something legal but worth knowing about.)
Galleria-corridor weight-loss clinics offering compounded semaglutide: Operations on and near Post Oak and Westheimer were quoting $299–$399/month, inclusive of the drug and a monthly telehealth check-in. Labs were quoted separately — but at least two clinics contacted described labs as “recommended but not required.” That phrase should give you pause. It gave me pause.
Montrose drip-spa hybrids: IV wellness studios in Montrose with semaglutide programs quoted $400–$600/month for compounded semaglutide, in some cases bundled with a monthly “metabolic IV drip” as a required part of the package. Requiring an unproven supplementary service as a condition of getting the prescription is a business model, not a clinical protocol. It’s a red flag.
Concierge primary care in Tanglewood/River Oaks: Practices in the Tanglewood area offering GLP-1 prescriptions as part of comprehensive primary care quoted $500–$800/month for brand-name medications for enrolled patients, with labs typically folded into an annual membership. These practices help patients work manufacturer savings programs. The clinical model is genuinely different here: a physician who knows your full chart, manages your other conditions, and can handle complications. You’re paying more. You’re also getting actual medicine.
Direct-to-consumer telehealth platforms (Hims, Noom Med, Calibrate, Found): Platforms serving Houston-area patients quoted roughly $199–$299/month for compounded semaglutide as of early 2025, actively navigating the post-shortage compliance question. Quality of clinical oversight varies significantly across these platforms — some conduct real video visits; others use asynchronous review only. Read the specific intake protocol before you enter a credit card number.
On price: if you paid $299/month at a clinic that skipped labs and ran your intake through a web form, you didn’t get a discount on Wegovy. You received a legally uncertain compounded product with minimal clinical oversight. That’s a different transaction entirely.
How to Verify Any Houston GLP-1 Clinic Before You Pay
The Texas Medical Board’s public license lookup is at tmb.state.tx.us. Navigate to License Verification and search by physician name. This takes about ninety seconds and you should do it before you hand over any money.
An “Active” license status is the floor. “Inactive,” “Expired,” or “Suspended” disqualifies a clinic. Don’t accept the staff’s verbal assurance. Check it yourself.
The lookup also shows any orders, sanctions, or pending complaints. A prior order doesn’t automatically disqualify a physician, but read the specifics. The TMB publishes full order records.
A physician whose only listed address is the clinic itself, with no hospital affiliations visible in the TMB record or in the Houston-area hospital medical staff directories (Houston Methodist, HCA Houston, and Memorial Hermann all publish these), is worth scrutinizing further. Physicians practicing legitimate obesity medicine typically maintain active hospital affiliations or academic appointments. A physician whose TMB record shows a Texas address that corresponds to a virtual or mail-drop location may be licensed in Texas while operating entirely from elsewhere — prescribing to Houstonians with no real presence here. Not automatically illegal. But it correlates with thin accountability when something goes wrong.
Check the TDLR facility database (tdlr.texas.gov) to confirm the clinic holds a current facility license. Search the Texas Secretary of State’s database (sos.state.tx.us) to see what legal entities are registered under the clinic’s name. A business registered only as an LLC with no separate professional entity is worth noting — in Texas, physician-owned practices must be structured as a professional limited liability company or professional association. If you’re unsure how Texas professional entity structures work, our coverage of business formation for Texas entrepreneurs breaks down the relevant distinctions.
Eight Signs a Clinic Is Cutting Clinical Corners
-
No verifiable medical director name on the website or in person. Any legitimate prescribing clinic can name the physician responsible for clinical protocols without hesitation. If they can’t, leave.
-
Text-only or chatbot intake with no synchronous physician interaction. A web form and an asynchronous questionnaire review doesn’t establish a physician-patient relationship under any reasonable clinical standard and likely violates TMB telemedicine rules.
-
No labs required before prescribing. This is the clearest single indicator that a clinic is selling a product rather than practicing medicine. Baseline labs catch contraindications. “Optional” labs are not a clinical standard.
-
Compounded semaglutide with no disclosed pharmacy source. Post-shortage, a clinic that won’t tell you which pharmacy compounded your medication and whether that pharmacy is currently licensed is either uninformed or concealing something. Both are problems.
-
Bundled services required as a condition of prescribing. IV drips, proprietary supplements, “metabolic boosters” — if you can’t decline the add-ons and still receive the prescription, that’s a revenue structure, not a treatment plan.
-
No protocol for managing side effects. Ask explicitly: what happens if I develop severe nausea and can’t keep fluids down? What’s your protocol if a patient presents with abdominal pain that might be pancreatitis? A clinic that stumbles on this question has no business prescribing the drug.
-
No pathway to specialist escalation. GLP-1 complications can require gastroenterology, endocrinology, or emergency care. A pure subscription service with no referral network and no relationship to the Houston hospital system can’t manage these when they arise. They will arise.
-
TDLR listing as a med spa with no corresponding medical entity in the Secretary of State’s database. The corporate structure of the prescribing entity is either absent or deliberately obscured. Both are red flags.
Med Spa, Weight-Loss Clinic, or Your Own Doctor
If you have Type 2 diabetes, cardiovascular disease, or significant metabolic comorbidities, start with your primary care physician or an endocrinologist — not a strip-mall clinic. GLP-1 medications in this context interact with existing medications and require coordination across your clinical relationships in ways that demand a physician who actually knows your chart. UTHealth Houston’s Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine’s Section of Endocrinology, and Houston Methodist’s Bariatric and Metabolic Institute all have physicians experienced in this.
If you’re otherwise healthy and pursuing weight management, a well-run weight-loss clinic or obesity medicine practice may be entirely appropriate — provided it clears the credential and protocol checks above. Look for physicians holding ABOM certification. The American Board of Obesity Medicine credential indicates specific training and examination in obesity medicine beyond general medical training. It’s not the only marker of a good physician, but it’s a meaningful one. The ABOM public directory is searchable at abom.org.
A med spa structure is the wrong clinical setting for patients with significant comorbidities, for patients whose complications require ongoing medical management, or frankly for any patient who just wants a physician who’ll pick up the phone. The strongest med spas in Houston have compensated for this by building genuine relationships with actively engaged medical directors. The weakest have a physician’s name on a certificate and nothing else. The credential checks above are how you tell them apart. More on these and similar issues appears across our health & wellness coverage.
What the TMB’s Complaint Record Does and Doesn’t Tell You
CityDesk Houston submitted a public information request to the Texas Medical Board seeking data on disciplinary actions and complaints against Houston-area physicians related to weight-loss prescribing and GLP-1 medications.
The TMB’s response confirmed the board doesn’t categorize complaints by drug class — so there’s no discrete count of GLP-1-specific enforcement actions. The board also noted that its processing backlog means many complaints filed in 2024 haven’t yet resulted in publicly visible orders.
That’s important. No formal enforcement record against a specific clinic doesn’t mean no complaints have been filed. A clinic that opened in 2023 with thin clinical oversight may have generated patient complaints still sitting in queue in 2025. If you believe a clinic prescribed to you without adequate evaluation, without honest disclosure of the compound’s legal status, or in a way that caused preventable harm, file a complaint at tmb.state.tx.us. You’ll need the physician’s name, a description of the conduct, and supporting documentation.
Filing doesn’t guarantee action. The TMB’s resources are finite and its backlog is real. But it’s one of the few accountability mechanisms that exists in this space, and it only works when patients actually use it.
The Houston GLP-1 market has real gaps — between what Texas law requires and what any single agency monitors, between what a clinic tells patients and what it documents, between how fast this market grew and how slowly oversight has moved. Those gaps are navigable if you go in with your eyes open.
The clinics doing this right have nothing to fear from any of these questions. Ask them anyway.
